RZLT vs XERS
RZLT: Rezolute is a late-stage biotech developer of ersodetug, an insulin receptor-targeting antibody aimed at treating rare forms of refractory hypoglycemia. XERS: Xeris Biopharma develops and commercializes innovative, ready-to-use therapeutic products for specialty medical conditions, leveraging proprietary formulation technologies.
Side-by-side fundamentals
| Metric | RZLT | XERS | Edge |
|---|---|---|---|
| Price as of 2026-10-08 close | $4.64 | $10.19 | |
| Market cap | $449M | $1.9B | |
| P/E as of 2026-10-08 | n/a | 183.60 | |
| Net margin FY2025, SEC XBRL | n/a | +0.2% | |
| Operating margin FY2025, SEC XBRL | n/a | +8.5% | |
| ROE | -77.1% | +4.0% | XERS higher |
| ROA | -68.8% | +0.1% | XERS higher |
| Debt / equity as of 2026-09-02 | 0.00 | 17.00 | RZLT lower |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +41.5% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +38.3% | |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-02 | 0.99 | 0.88 | |
| 1-year return as of 2026-10-08 close | -46.8% | +24.3% | XERS higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.